1 / 1

Chronic Migraine Severity Scale

Chronic Migraine Severity Scale. Mario F.P. Peres 1, Marcelo E Bigal 2 1. IIEP, Albert Einstein Hospital, Sao Paulo, SP, Brazil. 2. Neurology, Albert Einstein College of Medicine, New York, NY, USA. Grade I Grade II Grade III Grade IV

masao
Download Presentation

Chronic Migraine Severity Scale

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chronic Migraine Severity Scale Mario F.P.Peres 1, Marcelo E Bigal 2 1. IIEP, Albert Einstein Hospital, Sao Paulo, SP, Brazil. 2. Neurology, Albert Einstein College of Medicine, New York, NY, USA. Grade I Grade II Grade III Grade IV mild moderate severe very severe 0 25 50 75 100 CMSS ranges from 0 to 100 points, 0=no impact, 100= the highest impact. CMSS includes 4 impact categories, 0-25: mild, 26-50: moderate, 51-75: severe, 75-100: very severe. Frequency (0-30 days per month) scores one point for every headache day. Impact defined as a productivity loss higher than 50% in the day scores 0.5 for each affected day in the month. Analgesic use scores 0.5 for each day any analgesic was used. The comorbidity domain, comprising anxiety, mood-depression, bodily pain, and sleep quality each scores in a 0-10 subscale, in total 0-40.CMSS is potentially a useful clinical and research tool for evaluation and grading CM severity. CMSS could also be used in other chronic daily headaches. Different treatment strategies (hospitalization, outpatient treatment, non-pharmacological treatment, polytherapy) may be indicated based on the scale severity. Further studied are necessary for the scale improvement and validation. 30 Anxiety Mood Sleep Bodily Pain 15 15 10 10 10 10 frequency impact analgesic comorbidity This poster is available at www.cefaleias.com.br

More Related